Portola Pharmaceuticals Inc. (PTLA)

45.82
NASDAQ : Health Technology
Prev Close 45.02
Day Low/High 44.10 / 46.05
52 Wk Low/High 29.50 / 67.10
Avg Volume 918.00K
Exchange NASDAQ
Shares Outstanding 65.25M
Market Cap 2.93B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Portola Pharmaceuticals Stock Sees Short Interest Increase 14.2%

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 553,785 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 4,455,929, an increase of 14.19% since 12/29/2017.

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign To Raise Awareness About The Persistent Risk Of Blood Clots

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign To Raise Awareness About The Persistent Risk Of Blood Clots

Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States

Southwest Airlines, Delta Air Lines, GE: 'Mad Money' Lightning Round

Southwest Airlines, Delta Air Lines, GE: 'Mad Money' Lightning Round

Jim Cramer is bullish on Southwest, Delta, General Electric, and Portola Pharmaceuticals.

Real Story Behind Tech's Selloff: Cramer's 'Mad Money' Recap (Tuesday 9/26/17)

Real Story Behind Tech's Selloff: Cramer's 'Mad Money' Recap (Tuesday 9/26/17)

From Apple's orders and funds liquidating winners to the slow-growing cloud narrative, Jim Cramer explains why he thinks this is selloff is really an opportunity.

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Portola Pharmaceuticals, Inc. Investors (PTLA)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Portola Pharmaceuticals, Inc. Investors (PTLA)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Portola Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)